Article

Development and validation of the Immune Profile Score (IPS), a novel multi-omic algorithmic assay for stratifying outcomes in a real-world cohort of advanced solid cancer patients treated with immune checkpoint inhibitors

2024-11-05

Abstract excerpt

<h4>Background</h4> Immune checkpoint inhibitors (ICIs) have transformed the oncology treatment landscape. Despite substantial improvements for some patients, the majority do not benefit from ICIs, indicating a need for predictive biomarkers to better inform treatment decisions. <h4>Methods</h4> A de-identified pan-cancer cohort from the Tempus multimodal real-world database was used for the development and valida...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3705c946-641c-5da6-bea9-f7dfbb5d9dae
DOI: 10.1101/2024.11.05.24316583

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Development and validation of the Immune Profile Score (IPS), a novel multi-omic algorithmic assay for stratifying outcomes in a real-world cohort of advanced solid cancer patients treated with immune checkpoint inhibitorsDOI 10.1101/2024.11.05.24316583Read

Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data.Semantic proximity Read

Large-Scale Meta-Analysis of Potential Biomarkers for Treatment Response to Anti-PD-1/PD-L1 Immune Checkpoint InhibitorsSemantic proximity Read

Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade.Semantic proximity Read

Robust prediction of patient outcomes with immune checkpoint blockade therapy for cancer using common clinical, pathologic, and genomic featuresSemantic proximity Read

Improved prediction of immune checkpoint blockade efficacy across multiple cancer types.Semantic proximity Read

Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types.Semantic proximity Read

Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockadeSemantic proximity Read

HINS: HLA-mediated immunogenic neoantigen score for robust prediction of immune checkpoint blockade responseSemantic proximity Read

Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors.Semantic proximity Read

Biomarkers and Outcomes in Diverse Cancers: Meta-Analysis of Early Phase Immuno-Oncology TrialsSemantic proximity Read

Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors.Semantic proximity Read